ZURICH (dpa-AFX Broker) – The major Swiss bank UBS has left Sanofi’s rating at “neutral” with a price target of 100 euros based on quarterly figures and lowered expectations for the next two years. Due to a surprisingly high tax rate and increased investments in research and development, the French pharmaceutical company now expects a decline in earnings per share in the low single digits in 2024, wrote analyst Colin White in a study available on Friday. An increase in profits had previously been expected on the market./la/jha/
Publication of the original study: October 27, 2023 / 06:43 / GMT First distribution of the original study: October 27, 2023 / 06:43 / GMT
———————-
dpa-AFX Broker – the trader news from dpa-AFX
———————-
Selected leverage products on Sanofi
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Sanofi
The leverage must be between 2 and 20
Advertising